Authors





Alexandru Nicolae, MS

Latest:

Routine Breast Cancer Screening in Average-Risk Women Younger Than 50 Years: Current Paradigms Based on National Guidelines

Approximately 270,000 women are diagnosed with breast cancer each year in the United States alone. While there is consensus among national organizations including the US Preventive Services Task Force, the American Cancer Society, and the American College of Radiology that routine mammography screening should be performed in women 50 years and older, there is debate about the benefit-to-harm ratio of routine screening in average-risk women aged between 40 and 49 years. In this review, we examine risks and benefits of routine breast cancer screening starting at age 40 at the individual level, followed by evaluation of the role of advanced imaging techniques in screening women on a population level.


Alan H. Bryce, MD

Latest:

Deciding Which RP to Utilize

Experts discuss how to decide which robotic prostatectomy (RP) approach to utilize, considering factors such as patient characteristics, surgical outcomes, and the latest clinical evidence.



Hope E. Uronis, MD, MHS

Latest:

Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.




Kate Small, MS

Latest:

Building Efficiency and Scaling With a Remote Genetic Counseling Program

Smita K. Rao, MBBS, MS, et al gave an overview of implementing genetic counseling into oncology practices through telemedicine.


Ciara Kelly, MBBCh, BAO

Latest:

Toward Personalized Treatment Approaches in Soft Tissue Sarcomas

Ciara Kelly, MBBCh, BAO, discusses personalized treatment approaches for patients with soft tissue sarcoma.


Aasma Shaukat, MD, MPH

Latest:

Blood-Based Test May Help Increase Colorectal Cancer Screening Rates

Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.




Tarek Mekhail, MD

Latest:

Between the Lines™ Podcast: Mobocertinib Use in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive mNSCLC

Gregory Riely, MD, PhD, and Tarek Mekhail, MD, detailed the use of mobocertinib of platinum-pretreated patients with metastatic non–small cell lung cancer.



Viviana Cortlana, MS4

Latest:

Expanding Horizons in T-Cell Lymphoma Therapy: Focus on Personalized Treatment Strategies

Several lymphoma experts discuss the current T-cell lymphoma landscape, the need for new therapies, and ongoing research in the space.


Miranda Lankas

Latest:

Ra-223 Improves Outcomes in Prostate Cancer With Bone Metastases

Investigators observe low rates of treatment discontinuation and adverse effects with radium-223 as treatment for castration-resistant prostate cancer and bone metastases.





Jeff Hosry MD

Latest:

The Prognostic Significance of Peripheral Blood Biomarkers in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab: A Clinical Study

Kira MacDougall, MD, and co-investigators, research the importance of peripheral biomarkers in patients with advanced non–small cell lung cancer who are treated with pembrolizumab.




Janellen Smith, MD

Latest:

Unmet Needs and Future Perspectives in NSCLC Treatment

The panelists close their discussion on non-small cell lung cancer by emphasizing the need for continued research, early screening, and collaboration with dermatologists to address the unmet needs and improve overall outcomes.



Stephanie Eisenstat, MD

Latest:

Implementing a Multidisciplinary Lifestyle Medicine Clinic for Cancer Survivorship

The lifestyle medicine needs of cancer survivors seeking lifestyle consultation are growing, and awareness of the benefits of lifestyle medicine for this population can enhance the quality of life for patients who are survivors of cancer.



Helai Hussaini, MD

Latest:

Efficacy and Safety of Zolbetuximab in Gastric Cancer

Zolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.


Samer A. Srour, MB, ChB, MS

Latest:

Samer A. Srour, MB, ChB, MS, Reviewed Findings of CB-NK Cells and Elotuzumab Regimen in High-Risk Multiple Myeloma

A phase 2 study investigated the use of cord blood–derived natural killer cells plus elotuzumab, lenalidomide, and melphalan with autologous stem cell transplant for patients with high-risk multiple myeloma.